Mathias Buttmann

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

Sven Jarius, Klemens Ruprecht, Ingo Kleiter et al. · Journal of Neuroinflammation · 2016 · 891 citations · Full text

Medicine, Neurology, Neuroscience +15

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin

Sven Jarius, Klemens Ruprecht, Ingo Kleiter et al. · Journal of Neuroinflammation · 2016 · 428 citations · Full text

Medicine, Immunology, Neurology +16

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome

Sven Jarius, Ingo Kleiter, Klemens Ruprecht et al. · Journal of Neuroinflammation · 2016 · 250 citations · Full text

Medicine, Neurology, Neuroscience +17

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients

Florence Pache, Hanna Zimmermann, Janine Mikolajczak et al. · Journal of Neuroinflammation · 2016 · 243 citations · Full text

Medicine, Neurology, Neuroscience +16